MERCK announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending approval of Keytruda (pembrolizumab) for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tumor mutations.
Two months into his job as CEO of the American Cancer Society and American Cancer Society Cancer Action Network, Shane Jacobson is still in the drinking-water-from-the-firehose stage of the job.
